首页 > 市场调查报告书 > 能源/环境

电池

市场调查报告书

商品编码

1747314

第二代抗精神病药物市场依适应症、药物类别、给药途径、通路和地区划分

Second Generation Antipsychotics Market, By Indication, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2025年05月05日 | 出版商:

Coherent Market Insights | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计 2025 年全球第二代抗精神病药物市场规模为 102.5 亿美元，到 2032 年将达到 156.7 亿美元，2025 年至 2032 年的复合年增长率为 6.25%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	102.5亿美元
效能数据	从2020年到2024年	预测期	2025年至2032年
预测期：2025-2032年复合年增长率：	6.25%	2032年价值预测	156.7亿美元

近年来，由于精神疾病盛行率的上升和对有效治疗的需求的增加，全球第二代抗精神病药物市场出现了显着增长。第二代抗精神病药，也称为非典型抗精神病药，已成为治疗各种精神疾病的首选药物，包括思觉失调症、躁郁症和重度忧郁症。与第一代抗精神病药物相比，这些药物具有多种优势，包括疗效提高、锥体外系副作用减少和耐受性更好。受人们精神健康意识增强、新型製剂开发和适应症扩大的推动，第二代抗精神病药物市场预计将保持扩张趋势。

市场动态：

全球第二代抗精神病药物市场受到多种因素驱动，包括老年人口的成长和人们对精神健康意识的不断提高。根据世界卫生组织 (WHO) 估计，全球约有 4.5 亿人患有精神疾病，对有效治疗的需求庞大。此外，第二代抗精神病药物长效注射剂型的开发提高了患者的依从性和便利性，进一步促进了市场成长。然而，市场限制因素包括这些药物成本高、可能产生的副作用以及与精神疾病相关的耻辱感。关键药物专利到期和学名药的出现也可能影响市场动态。儘管如此，由于对个人化机会的日益关注、新型药物输送系统的市场开发以及第二代抗精神病药物在其他精神疾病治疗中的应用不断扩大，市场仍然存在巨大的成长机会。

本研究的主要特点

本报告对全球第二代抗精神病药物市场进行了详细分析，并以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
它还强调了各个领域的潜在商机，并说明了该市场的有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
它根据公司亮点、产品系列、关键亮点、财务表现和策略等参数，介绍了全球第二代抗精神病药物市场的主要企业概况。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。
全球第二代抗精神病药物市场报告针对该行业的各个相关人员，包括投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员将透过用于分析全球第二代抗精神病药物市场的各种策略矩阵更轻鬆地做出决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 10.25 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.25%	2032 Value Projection:	USD 15.67 Bn

The global second generation antipsychotics market has witnessed significant growth in recent years, driven by the increasing prevalence of mental health disorders and the rising demand for effective treatments. Second generation antipsychotics, also known as atypical antipsychotics, have emerged as a preferred choice for the management of various psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder. These medications offer several advantages over first generation antipsychotics, such as improved efficacy, reduced extrapyramidal side effects, and better tolerability. The market for second generation antipsychotics is expected to continue its upward trajectory, fueled by the growing awareness about mental health, the development of novel formulations, and the expanding indications for these drugs.

Market Dynamic:

The global second generation antipsychotics market is driven by several factors, including the growing geriatric population, and the increasing awareness about mental health. The World Health Organization estimates that around 450 million people globally suffer from mental health disorders, creating a significant demand for effective treatments. Additionally, the development of long-acting injectable formulations of second generation antipsychotics has improved patient compliance and convenience, further driving market growth. However, the market also faces certain restraints, such as the high cost of these medications, the potential for side effects, and the stigma associated with mental health disorders. Patent expiration of key drugs and the emergence of generic alternatives may also impact the market dynamics. Nevertheless, the market presents substantial opportunities for growth, driven by the increasing focus on personalized medicine, the development of novel drug delivery systems, and the expanding applications of second generation antipsychotics in the treatment of other psychiatric disorders.

Key Features of the Study:

This report provides in-depth analysis of the global second generation antipsychotics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global second generation antipsychotics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Johnson & Johnson, Eli Lilly and Company, AstraZeneca, Bristol-Myers Squibb, Pfizer, Novartis, Otsuka Pharmaceutical, Lundbeck, Sanofi, Merck & Co., AbbVie, Takeda Pharmaceutical, Amgen, GlaxoSmithKline, and Alkermes
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global second generation antipsychotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global second generation antipsychotics market

Market Segmentation

Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Schizophrenia
- Bipolar Disorder
- Major Depressive Disorder
- Autism Spectrum Disorder
- Other Indications
Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Risperidone
- Quetiapine
- Olanzapine
- Aripiprazole
- Asenapine
- Clozapine
- Paliperidone
- Brexpiprazole
- Lurasidone
- Others
Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Johnson & Johnson
- Eli Lilly and Company
- AstraZeneca
- Bristol-Myers Squibb
- Pfizer
- Novartis
- Otsuka Pharmaceutical
- Lundbeck
- Sanofi
- Merck & Co.
- AbbVie
- Takeda Pharmaceutical
- Amgen
- GlaxoSmithKline
- Alkermes

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Second Generation Antipsychotics Market, By Indication
- Global Second Generation Antipsychotics Market, By Drug Class
- Global Second Generation Antipsychotics Market, By Route of Administration
- Global Second Generation Antipsychotics Market, By Distribution Channel
- Global Second Generation Antipsychotics Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Driver
- Restraint
- Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Second Generation Antipsychotics Market, By Indication, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Schizophrenia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Major Depressive Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Autism Spectrum Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Other Indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Second Generation Antipsychotics Market, By Drug Class, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Risperidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Quetiapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Olanzapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Aripiprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Asenapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Clozapine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Paliperidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Brexpiprazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Lurasidone
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Second Generation Antipsychotics Market, By Route of Administration, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Second Generation Antipsychotics Market, By Distribution Channel, 2020-2032, (USD Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Second Generation Antipsychotics Market, By Region, 2020 - 2032, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Otsuka Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Lundbeck
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Takeda Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Alkermes
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

第二代抗精神病药物市场依适应症、药物类别、给药途径、通路和地区划分